Lineage Cell Therapeutics to Apply Allogeneic Dendritic Cell Therapy Program to COVID-19 Vaccine Development

CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #COVID19–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it has applied for grant funding from the California Institute for Regenerative Medicine (CIRM) to support the use of VAC, Lineage?s allogeneic dendritic cell therapy, toward the development of a potential vaccine against SARS-CoV-2, the virus which causes COVID-19. In response to t